← Back

Wire · operational-macro

Novo Gets FDA Approval For First-Of-Its-Kind Weekly Growth Hormone Treatment For ...

Published

20 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at stocktwits.com →

◆ Verified

Fusion42 · 20 November 2026 · Fusion42 review

The FDA has approved Novo Nordisk's once-weekly growth hormone treatment, Sogroya, for children aged 2.5 and older with growth failure due to Turner syndrome. The treatment offers comparable growth to daily injections while significantly reducing the number of annual injections.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 20 Nov 2026 and 21 Nov 2026.

◆ ◆ The Wire takeaway

You now have a new growth hormone treatment option for Turner syndrome that cuts injection frequency drastically. This shifts patient compliance and care models for paediatric rare diseases with hormone treatments.

◆ Coverage

2 sources · first reported 20 Nov 2026 · latest 21 Nov 2026

◆ Related on Wire

◆ Topics

BiotechFDA-approvalgrowth-hormoneturner-syndromerare-diseasebiotech